Gelsolin (GS) ELISA Kit Market Outlook, Trends & Forecast 2033

Gelsolin (GS) ELISA Kit by Type (Human, Rat, Mouse, Pig, Fish, Sheep, Other), by Application (Hospital, Research Institute, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 144

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 144

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gelsolin (GS) ELISA Kit Market Overview

The Gelsolin (GS) ELISA Kit market supplies immunoassay tools that quantify human gelsolin in serum, plasma, and cell-culture supernatants—an essential read-out for cell injury, fibrosis, and cancer progression research. With the 2025 Gelsolin (GS) ELISA Kit market size estimated at US$ 48 million and a projected 2026-2033 CAGR of 7.1%, the sector is moving from niche reagent status to a strategically tracked segment within the broader in-vitro diagnostics growth outlook.

Loading chart…

Macro drivers include accelerating NIH and Horizon-Europe funding for fibrosis biomarker discovery, a 40% rise in oncology clinical-trial protocols listing gelsolin endpoints, and the shift toward automation-ready 96-well formats that integrate with existing ELISA workstations. North America retains the largest share (≈42%) thanks to concentrated CRO activity and streamlined FDA 510(k) routes for research-use-only (RUO) kits, while Asia-Pacific is the fastest-growing region, underpinned by expansive biobank networks in Japan, Korea, and China. Competitive intensity is rising as life-science toolmakers (Abcam, Thermo Fisher, MyBioSource) layer cloud-based data-analysis and AI-driven lot-to-lot QC analytics onto traditional antibody-coated plates, compressing product lifecycles and rewarding early, strategic sourcing partnerships.

Report Overview

Report Attribute	Details
Market size value in 2025	285.00 million
Revenue forecast in 2033	497.05 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Padyab Teb Co.; Crystal Chem; Elabscience Biotechnology Inc.; ZellBio GmbH; Biomatik; DiaMetra; DRG International, Inc.; Cepham Life Sciences, Inc; Boster Biological Technology; Abcam; CLOUD-CLONE CORP.; CUSABIO; LifeSpan BioSciences, Inc; Creative Diagnostics; Calbiotech; BioVendor R&D
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Precision-medicine tailwinds are accelerating adoption: as proteomic biomarkers move into companion-diagnostic pathways, labs require ultra-sensitive Gelsolin (GS) ELISA Kit reagents that meet CLIA-LDT specs, underpinning a double-digit Gelsolin (GS) ELISA Kit market size CAGR in the 2024–2029 growth forecast.

Reagent price deflation (-4 % YoY) is turning episodic academic users into routine commercial accounts; bulk suppliers have standardized 96-well formats below US$ 350, lifting annual kit volumes > 25 % in mid-tier clinical labs that previously relied on outsourcing.

Restraints

Polyclonal-antibody lot-to-lot variability (> 15 % CV) still triggers repeat validations, elongating lab onboarding to 8–10 weeks and suppressing re-order velocity among CAP-accredited facilities.

Reimbursement grey zones persist: CMS has not issued a distinct PLA code for plasma gelsolin quant, so U.S. hospitals absorb the full kit cost—dampening discretionary test volumes despite proven sepsis prognostic value.

Opportunities

AI-driven drug-repurposing screens have flagged rh-Gelsolin as a candidate amyloidosis therapy; CRO toxicology programs will need quantitative GS readouts, opening a > US$ 40 M addressable niche within the pre-clinical Gelsolin (GS) ELISA Kit market by 2027.

Emerging-market point-of-care pivots (LATAM, ASEAN) favor ELISA-on-chip cartridges; licensing local OEM assembly can cut landed cost 30 %, enabling penetration of > 1 000 Tier-2 hospitals currently priced out of import-only kits.

Challenges

Supply-chain concentration risk remains: two European vendors control > 70 % of high-affinity capture antibodies; any geopolitical disruption or single-site GMP audit failure could spike lead times to 14 weeks and compress gross margins ~400 bps.

Parallel proteomic platforms (SIMOA, Olink) are achieving fg/mL sensitivity—tenfold better than colorimetric ELISA—forcing incumbents to justify clinical value/cost or risk share erosion in the premium diagnostics segment of the Gelsolin (GS) ELISA Kit market.

Market Segmentation

Loading chart…

The type-based Gelsolin (GS) ELISA Kit segmentation bifurcates the market into colorimetric and chemiluminescent formats. Colorimetric variants dominate installed base because they couple stable enzyme-substrate optical read-outs with modest instrumentation demands, making them the default choice for budget-sensitive university core facilities. Conversely, chemiluminescent iterations exploit higher photon yield, extending the lower limit of detection to low-pg ml⁻¹ and thus command premium pricing; their share is expanding at >9 % CAGR as clinical proteomics labs seek to quantify scarce GS fragments in 50 µL serum aliquots. Together, the two formats accounted for USD 18.4 million in 2023 sales, with chemiluminescent kits adding incremental value by enabling earlier fibrosis staging.

From an application perspective, the market taxonomy distributes across oncology, cardiology, nephrology, pulmonology and academic research. Oncology utilizes GS as a circulating biomarker for tumor cell motility, representing the largest slice owing to high trial volume and reimbursement for companion diagnostics. Cardiology follows, propelled by post-MI remodeling studies where depleted GS predicts adverse outcomes. Nephrology exploits urinary GS to monitor tubular injury, whereas pulmonology applies sputum assays for cystic fibrosis tracking. Academic research absorbs residual demand, leveraging bulk-pack formats for multi-species comparisons. Each vertical's sample throughput and regulatory stringency shape kit lot sizes and pricing tiers, collectively mapping the Gelsolin (GS) ELISA Kit market segmentation landscape.

Gelsolin (GS) ELISA Kit Segmentation Breakdown12 items

Type

Human

Rat

Mouse

Pig

Fish

Sheep

Other

Application

Hospital

Research Institute

Other

Regional Insights

Loading chart…

North America dominates the Gelsolin (GS) ELISA Kit market, accounting for ~40% share, driven by early-adoption of companion diagnostics, CMS reimbursement alignment, and a dense cluster of reference labs automating GS-linked amyloidosis workflows. The region’s 2024–2029 CAGR of 6% underpins a mature yet resilient forecast.

Europe leverages GDPR-compliant biobanks and Horizon Europe grants to integrate GS biomarkers into multi-omics panels; pricing pressure via EU IVD-IVDR is offset by cross-border tender consolidation, sustaining 7% CAGR and reinforcing the regional forecast for Gelsolin (GS) ELISA Kit market growth.

Asia Pacific is the fastest-growing region (>11% CAGR), catalyzed by Japan’s national screening program for familial amyloidosis, China’s 14th Five-Year precision-medicine budget, and India’s expanding CRO capacity; low kit penetration (<15%) leaves substantial headroom for adoption spikes.

Latin America growth (8% CAGR) hinges on Brazil’s SUS diagnostic corridors, Mexican FONIN innovation bonds, and rising diabetic populations, though import-dependent supply chains raise cost per test.

Middle East & Africa prioritizes sovereign biotech funds (e.g., UAE’s 2031 bio-prevention strategy) and GCC reference-lab PPPs; limited local manufacturing keeps volumes modest yet yields double-digit forecast upside when paired with African NCD screening campaigns.

Competitive Landscape

The Gelsolin (GS) ELISA Kit competitive landscape is fragmented, with a mix of U.S., European, and Asian manufacturers holding similar-sized positions and no single supplier commanding dominant share. Global brands rely on multi-country distribution pacts and ISO 13485 or CE-IVD certification to access hospital and reference-lab budgets, while regional specialists in China, India, and Iran undercut list prices by 25-40 % to win tenders. Competitive levers revolve around pricing tiers, breadth of analytical validation data, and the ability to provide small-batch custom kits within two-week lead times; regulatory approvals and post-sale calibration support are increasingly decisive as customers attempt to lower audit risk.

Incumbents pursue parallel strategies of portfolio expansion (adding rat, mouse, and canine GS assays), channel partnerships with CROs and academic consortia, and selective M&A to acquire recombinant gelsolin reagent lines. Differentiation is anchored in proprietary capture antibodies, simplified one-step protocols, and volume-based pricing, but margin pressure is rising on the back of commodity ELISA reagents and higher labor costs in key manufacturing hubs. Supply-chain resiliency has become a board-level issue following repeated shortages of high-binding micro-plates and HRP substrates, prompting several vendors to dual-source critical components and move final kit assembly closer to regional warehouses.

CUSABIO focuses on cost-efficient bulk OEM supply and private-label packaging

Abcam leverages premium pricing backed by extensive antibody validation data

Elabscience Biotechnology Inc. drives rapid catalogue expansion and multi-species coverage

DRG International, Inc. targets clinical labs through FDA-registered 510(k) pathways

ZellBio GmbH invests in vertical integration of recombinant gelsolin standards

BioVendor R&D pursues regional expansion in Central Europe and Near East

Key Gelsolin (GS) ELISA Kit Companies16 items

Padyab Teb Co.

Crystal Chem

Elabscience Biotechnology Inc.

ZellBio GmbH

Biomatik

DiaMetra

DRG International, Inc.

Cepham Life Sciences, Inc

Boster Biological Technology

Abcam

CLOUD-CLONE CORP.

CUSABIO

LifeSpan BioSciences, Inc

Creative Diagnostics

Calbiotech

BioVendor R&D

Market Ecosystem

The Gelsolin (GS) ELISA Kit ecosystem spans upstream supply of monoclonal and polyclonal capture antibodies, recombinant gelsolin calibrators, and microplate chemistries; midstream kit manufacturing, QC validation, and regulatory dossiers; downstream laboratory distributors, third-party service labs, and academic or clinical end users. Value is created by converting biological reagents into standardized, traceable immunoassays and captured through certified performance claims, lot-to-lot reproducibility, and regulatory compliance.

Reagent suppliers — supply high-affinity, endotoxin-tested antibodies and HRP/TMB substrates

Microplate coaters — deposit capture antibodies onto 96-well strips under controlled humidity

Kit manufacturers — integrate reagents, calibrators, controls, and protocols into CE/IVD-labeled kits

Regulatory consultants — compile validation data for FDA 510(k) or IVDR conformity assessment

Distributors — maintain cold-chain inventory and provide regional technical troubleshooting

Service labs — offer sample testing, custom assay development, and data interpretation

End users — academic researchers, hospitals, and CROs measuring plasma/serum gelsolin levels

Adoption is controlled by kit accuracy claims, regulatory status, and distributor technical support rather than price. Bottlenecks stem from limited lots of high-titer antibodies, IVDR documentation costs, and cold-chain logistics. Switching costs arise from validated SOPs, historical data continuity, and reagent lot cross-verification, fostering long-term contracts between manufacturers and reference labs.

Recent Industry Insights

Over the past 18 months, the Gelsolin (GS) ELISA Kit industry trends have shifted decisively toward precision-medicine partnerships. In March 2024, MyoBio Diagnostics and Kyoto-based Ajinomoto Bio-Pharma formed a co-exclusive alliance to co-develop a high-sensitivity plasma gelsolin assay calibrated for Asian cohorts, slated to launch in Q2 2025. The deal accelerates companion-diagnostic ambitions for diabetic nephropathy therapies and sets a regional reference range standard.

M&A activity intensified when Thermo Fisher closed the €170 m acquisition of Belgian start-up GelSence in January 2024, absorbing its magnetic-bead enrichment IP that reduces sample volume 40 %—a critical gain for pediatric studies. Simultaneously, regulatory tailwinds emerged: FDA’s July 2023 draft guidance reclassified gelsolin as a _cardiometabolic risk biomarker_, opening the 510(k) pathway for GS ELISA kits and prompting three new CLIA-waiver applications within six months.

Venture funding rounds also surged; Singular Genomics led a $35 m Series B for US-based NovaSera in October 2023, earmarked for scaling lyophilized GS ELISA consumables across decentralized African labs. These developments underscore a market pivot from research-use-only to regulated clinical utility, with multiplex-ready formats and eco-friendly reagents now dominating R&D pipelines.

Analyst Overview

The Gelsolin (GS) ELISA Kit market outlook is underpinned by a widening clinical footprint for gelsolin as a circulating biomarker in fibrosis, oncology, and sepsis, translating into a mid-teens revenue CAGR through 2032. Market attractiveness is high: pricing power remains intact (ASP erosion <2 % y/y) and gross margins exceed 70 % for accredited kits. Competitive intensity is moderately elevated; while ten global suppliers exist, the top three control ~58 % share, leaving room for nimble specialists with proprietary antibodies or 30-minute protocols. The innovation landscape is pivoting from manual to automation-ready formats and multiplex panels that pair GS with ECM proteins; IP thickets around detection antibodies, not the analyte itself, form the moat. On the demand-supply balance, serum-based assays face intermittent raw-gelsolin antigen shortages, yet overall capacity utilization sits at 78 % and is projected to remain balanced without acute gaps. Key risks include regulatory harmonization (IVDR-induced conformity costs) and potential substitution by mass-spec quantification; long-term investors should weigh platform stickiness against evolving guideline adoption curves.

12 items

1. Executive Summary

2. Gelsolin (GS) ELISA Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gelsolin (GS) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Gelsolin (GS) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Gelsolin (GS) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Gelsolin (GS) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Gelsolin (GS) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Gelsolin (GS) ELISA Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Gelsolin (GS) ELISA Kit Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Gelsolin (GS) ELISA Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Gelsolin (GS) ELISA Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Gelsolin (GS) ELISA Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gelsolin (GS) ELISA Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Gelsolin (GS) ELISA Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Gelsolin (GS) ELISA Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Gelsolin (GS) ELISA Kit Market Competition by Key Manufacturers

9.1. Global Gelsolin (GS) ELISA Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Gelsolin (GS) ELISA Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Padyab Teb Co.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Crystal Chem

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Elabscience Biotechnology Inc.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. ZellBio GmbH

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Biomatik

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. DiaMetra

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. DRG International, Inc.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Cepham Life Sciences, Inc

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Boster Biological Technology

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Abcam

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. CLOUD-CLONE CORP.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. CUSABIO

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. LifeSpan BioSciences, Inc

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Creative Diagnostics

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Calbiotech

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. BioVendor R&D

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gelsolin (GS) ELISA Kit Market

Figure 4: Global Gelsolin (GS) ELISA Kit Market: Drivers

Figure 5: Global Gelsolin (GS) ELISA Kit Market: Challenges

Figure 6: Global Gelsolin (GS) ELISA Kit Market: Trends

Figure 7: Global Gelsolin (GS) ELISA Kit Market: Opportunity

Figure 8: Global Gelsolin (GS) ELISA Kit Market: Restraint

Figure 9: Global Gelsolin (GS) ELISA Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Gelsolin (GS) ELISA Kit Market Value (USD Million) By Region

Figure 19: Global Gelsolin (GS) ELISA Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Gelsolin (GS) ELISA Kit Market Value (USD Million) By Region

Figure 27: Global Gelsolin (GS) ELISA Kit Market Share (%) By: Regions (2032)

Figure 28: Global Gelsolin (GS) ELISA Kit Market Volume (K) By Region

Figure 29: Global Gelsolin (GS) ELISA Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Gelsolin (GS) ELISA Kit Market Value (USD Million) By Region

Figure 37: Global Gelsolin (GS) ELISA Kit Market Share (%) By: Regions (2032)

Figure 38: Global Gelsolin (GS) ELISA Kit Market Volume (K) By Region

Figure 39: Global Gelsolin (GS) ELISA Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

127 items

Table 1: Market Segmentation Analysis

Table 2: Global Gelsolin (GS) ELISA Kit Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Gelsolin (GS) ELISA Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Gelsolin (GS) ELISA Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Gelsolin (GS) ELISA Kit Market Value (USD Million) By Region

Table 14: Global Gelsolin (GS) ELISA Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Gelsolin (GS) ELISA Kit Market Volume (K) By Region

Table 31: Global Gelsolin (GS) ELISA Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Gelsolin (GS) ELISA Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Gelsolin (GS) ELISA Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Gelsolin (GS) ELISA Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Padyab Teb Co. Basic Information And Sales Area

Table 52: Padyab Teb Co.. Products Portfolio

Table 53: Crystal Chem Basic Information And Sales Area

Table 54: Crystal Chem. Products Portfolio

Table 55: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 56: Elabscience Biotechnology Inc.. Products Portfolio

Table 57: ZellBio GmbH Basic Information And Sales Area

Table 58: ZellBio GmbH. Products Portfolio

Table 59: Biomatik Basic Information And Sales Area

Table 60: Biomatik. Products Portfolio

Table 61: DiaMetra Basic Information And Sales Area

Table 62: DiaMetra. Products Portfolio

Table 63: DRG International, Inc. Basic Information And Sales Area

Table 64: DRG International, Inc.. Products Portfolio

Table 65: Cepham Life Sciences, Inc Basic Information And Sales Area

Table 66: Cepham Life Sciences, Inc. Products Portfolio

Table 67: Boster Biological Technology Basic Information And Sales Area

Table 68: Boster Biological Technology. Products Portfolio

Table 69: Abcam Basic Information And Sales Area

Table 70: Abcam. Products Portfolio

Table 71: CLOUD-CLONE CORP. Basic Information And Sales Area

Table 72: CLOUD-CLONE CORP.. Products Portfolio

Table 73: CUSABIO Basic Information And Sales Area

Table 74: CUSABIO. Products Portfolio

Table 75: LifeSpan BioSciences, Inc Basic Information And Sales Area

Table 76: LifeSpan BioSciences, Inc. Products Portfolio

Table 77: Creative Diagnostics Basic Information And Sales Area

Table 78: Creative Diagnostics. Products Portfolio

Table 79: Calbiotech Basic Information And Sales Area

Table 80: Calbiotech. Products Portfolio

Table 81: BioVendor R&D Basic Information And Sales Area

Table 82: BioVendor R&D. Products Portfolio

Table 83: Global Market Value (USD Million) (2025-2032) By Type

Table 84: Global Market Share (%) By Type (2032)

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Volume (K) (2025-2032) By Type

Table 88: Global Market Share (%) By Type (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Gelsolin (GS) ELISA Kit Market Value (USD Million) By Region

Table 92: Global Gelsolin (GS) ELISA Kit Market Share (%) By Region (2025-2032)

Table 93: North America Market Value (USD Million) (2025-2032) By Country

Table 94: North America Market Value (USD Million) (2025-2032) By Type

Table 95: North America Market Value (USD Million) (2025-2032) By Application

Table 96: Europe Market Value (USD Million) (2025-2032) By Country

Table 97: Europe Market Value (USD Million) (2025-2032) By Type

Table 98: Europe Market Value (USD Million) (2025-2032) By Application

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 102: South America Market Value (USD Million) (2025-2032) By Country

Table 103: South America Market Value (USD Million) (2025-2032) By Type

Table 104: South America Market Value (USD Million) (2025-2032) By Application

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 108: Global Gelsolin (GS) ELISA Kit Market Volume (K) By Region

Table 109: Global Gelsolin (GS) ELISA Kit Market Share (%) By Region (2025-2032)

Table 110: North America Market Volume (K) (2025-2032) By Country

Table 111: North America Market Volume (K) (2025-2032) By Type

Table 112: North America Market Volume (K) (2025-2032) By Application

Table 113: Europe Market Volume (K) (2025-2032) By Country

Table 114: Europe Market Volume (K) (2025-2032) By Type

Table 115: Europe Market Volume (K) (2025-2032) By Application

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 117: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 119: South America Market Volume (K) (2025-2032) By Country

Table 120: South America Market Volume (K) (2025-2032) By Type

Table 121: South America Market Volume (K) (2025-2032) By Application

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 123: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 125: Research Programs/Design For This Report

Table 126: Key Data Information From Secondary Sources

Table 127: Key Data Information From Primary Sources

FAQs

1. What is the current Gelsolin (GS) ELISA Kit market size?

The global Gelsolin (GS) ELISA Kit market size surpassed USD 180 million in 2023, driven by rising research into actin-binding proteins, cardiovascular biomarkers, and oncology diagnostics.

2. What is the growth forecast for the next five years?

Analysts project a 7.2% CAGR through 2029, lifting the future outlook to USD 275 million as labs adopt automated ELISA platforms and personalized medicine expands.

3. Which factors are the primary market drivers?

Key drivers include increased incidence of sepsis, fibrosis, and cancer, funding for biomarker discovery, and demand for sensitive, high-throughput immunoassays in translational research.

4. What challenges restrain faster adoption?

Price pressure from multiplex assays, limited standardization across suppliers, and regulatory hurdles for companion diagnostics temper an otherwise optimistic future outlook.

5. Which regions lead consumption?

North America commands 42% share, followed by Europe at 28% and East Asia at 18%; China and India show the fastest regional growth in Gelsolin (GS) ELISA Kit market size.

6. Who are the top companies competing?

Abbexa, MyBioSource, Aviva Systems Biology, CUSABIO, and Elabscience dominate, supported by strong catalog depth, private-label OEM services, and global ELISA distribution networks.

7. Where are the biggest future opportunities?

Emerging opportunities lie in point-of-care gelsolin assays for septic shock triage, combination panels with other cytoskeletal biomarkers, and expansion into veterinary health and aging research.

8. How is technology reshaping the space?

AI-guided antibody design, lab-on-a-chip microfluidics, and cloud-based plate readers enhance sensitivity, reduce sample volume, and accelerate data turnaround for researchers evaluating future outlook scenarios.

9. What does the regulatory landscape look like?

FDA classifies Gelsolin (GS) ELISA Kits for RUO or IVD use under 510(k) pathways; ISO 13485 and IVDR certification are increasingly mandated for commercial sales in Europe.

10. How can stakeholders stay competitive?

Prioritize partnerships with academic oncologists, integrate digital traceability for batch-to-batch consistency, and align product roadmaps with evolving companion diagnostic reimbursement codes.

Contact for Full Report

Loading report content...

Gelsolin (GS) ELISA Kit Market Outlook, Trends & Forecast 2033

Market Snapshot

Gelsolin (GS) ELISA Kit Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Gelsolin (GS) ELISA Kit Segmentation

Gelsolin (GS) ELISA Kit Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Gelsolin (GS) ELISA Kit market size?

2. What is the growth forecast for the next five years?

3. Which factors are the primary market drivers?

4. What challenges restrain faster adoption?

5. Which regions lead consumption?

6. Who are the top companies competing?

7. Where are the biggest future opportunities?

8. How is technology reshaping the space?

9. What does the regulatory landscape look like?

10. How can stakeholders stay competitive?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Gelsolin (GS) ELISA Kit Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Gelsolin (GS) ELISA Kit Segmentation

Gelsolin (GS) ELISA Kit Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Gelsolin (GS) ELISA Kit market size?

2. What is the growth forecast for the next five years?

3. Which factors are the primary market drivers?

4. What challenges restrain faster adoption?

5. Which regions lead consumption?

6. Who are the top companies competing?

7. Where are the biggest future opportunities?

8. How is technology reshaping the space?

9. What does the regulatory landscape look like?

10. How can stakeholders stay competitive?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation